Equity Overview
Price & Market Data
Price: $6.11
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $25,347,336
Daily Volume: 0
Performance Metrics
1 Week: -1.93%
1 Month: 6.08%
3 Months: 13.99%
6 Months: 1.92%
1 Year: 98.48%
YTD: -1.29%
Company Details
Employees: 6
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.